Source - RNS
RNS Number : 1265M
Advanced Oncotherapy PLC
10 October 2016
 

 

10 October 2016

 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Directorate Change

 

As mentioned in the annual report for the year ended 31 December 2015 and in the 2016 notice of Annual General Meeting, Advanced Oncotherapy confirms that Mr Kanoria has stepped down from the board of the Company.

 

Advanced Oncotherapy Plc 

www.avoplc.com 

Michael Sinclair, CEO 

Tel: +44 20 3617 8728 

Nicolas Serandour, CFO & COO  

 

 

 

Stockdale Securities (Nomad & Joint Broker) 

 

Antonio Bossi / David Coaten 

Tel: +44 20 7601 6100 

 

 

Beaufort Securities (Joint Broker) 

 

Jon Belliss / Elliott Hance

Tel: +44 20 7382 8300

 

 

Walbrook PR (Financial PR & IR) 

Tel: +44 20 7933 8780 or [email protected] 

Paul McManus / Anna Dunphy 

Mob: +44 7980 541 893 / Mob: +44 7876 741 001 

 



 

About Advanced Oncotherapy plc www.avoplc.com 

 

Advanced Oncotherapy is a provider of particle therapy systems with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology providing better health outcomes and fewer treatment related side effects.

 

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology ("LIGHT"). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a linear way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

The Company has signed two purchase agreements for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

 

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc, to operate the Company's proton beam cancer therapy centre in Harley Street.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGGPCUUPQGUU

Related Charts

Advanced Oncotherapy (AVO)

0.00 (0.00%)
delayed 18:15PM